We are very happy to announce the launch of Version One Ventures III with $45M…
News, Version One
At Version One, we are strong believers that early-stage investing is best done by small teams that are aligned around a differentiated investment thesis and are investing with high conviction. The partnership is currently Angela and myself. We’re on our fourth fund and second opportunity fund, and we are looking to add a third partner […]
We are very happy to announce the launch of Version One Ventures III with $45M…
It has been almost 10 years since Union Square Ventures launched the first Opportunity Fund,…
At Version One, we are strong believers that early-stage investing is best done by small teams that are aligned around a differentiated investment thesis and are investing with high conviction. The partnership is currently Angela and myself. We’re on our fourth fund and second opportunity fund, and we are looking to add a third partner over the course of the next year or so.
We like to invest at the edges, not in the mainstream. We like to lead, not follow. We are comfortable betting on founders without (obvious) pedigree. We like to back mission-driven founders that are early in new areas. We love investing in people, not necessarily in existing traction and numbers. And we’re happy to back first-time entrepreneurs that nobody has ever backed.
We’ve got a strong conviction in the type of founders we like to invest in…and we’re just as clear as to the type of partner we are looking for as our 3rd partner:
What does not matter:
What we’re not looking for:
There is no formal application process for this role. Please find us on the Internet and reach out in the most meaningful way that reflects what we are looking for. We look forward to meeting you.
Health / Biology, Portfolio, Version One
Shifting healthcare systems from reactive to proactive care is critical – the best outcomes occur when people can take action early, before a condition becomes a diagnosis. That’s why we are excited to announce that we have led a $2.5m pre-seed round for NiaHealth and are thrilled that they are coming out of stealth and […]
We are continually refining our thesis on healthcare, from looking at clinical-grade at-home diagnostics to biotech and…
Over the past year, some of the most interesting and intellectually-stimulating pitches we heard have…